Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn’s disease

Kohoutová, Darina; Drahosova, Marcela; Morávková, Paula; Rejchrt, Stanislav; Bureš, Jan

doi:10.1186/s12876-014-0190-1

Cited by 14 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, no significant difference on the correlation of anti-GP2 IgG with disease location was observed in Czech Republic CD patients. 29 Bogdanos et al revealed the association between anti-GP2 IgG with structuring behavior (B2) and perianal disease in CD patients. 17 However, no significant difference of anti-GP2 IgG with structuring behavior (B2) and perianal disease was observed in our study with Chinese CD patients.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease

Zhang¹,

Luo

et al. 2015

Medicine

View full text Add to dashboard Cite

The need for reliable biomarkers for distinguishing Crohn disease (CD) from ulcerative colitis (UC) is increasing. This study aimed at evaluating the diagnostic potential of anti-GP2 antibodies as a biomarker in Chinese patients with CD. In addition, a variety of autoantibodies, including anti-saccharomyces cerevisiae antibodies (ASCA), perinuclear anti-neutrophil cytoplasmic antibodies (PANCA), anti-intestinal goblet cell autoantibodies (GAB), and anti-pancreatic autoantibodies (PAB), were evaluated.A total of 91 subjects were prospectively enrolled in this study, including 35 patients with CD, 35 patients with UC, 13 patients with non-IBD gastrointestinal diseases as disease controls (non-IBD DC), and 8 healthy controls (HC). The diagnosis of IBD was determined based on the Lennard-Jones criteria, and the clinical phenotypes of the IBD patients were determined based on the Montreal Classification.Anti-GP2 IgG antibodies were significantly elevated in patients with CD, compared with patients with UC (P = 0.0038), HC (P = 0.0055), and non-IBD DC (P = 0.0063). The prevalence of anti-GP2 IgG, anti-GP2 IgA and anti-GP2 IgA, or IgG antibodies in patients with CD was 40.0%, 37.1%, and 54.3%, respectively, which were higher than those in non-IBD DC (anti-GP2 IgG, 15.4%; anti-GP2 IgA, 7.7%; and anti-GP2 IgA or IgG, 23.1%) and those in patients with UC (anti-GP2 IgG, 11.4%; anti-GP2 IgA, 2.9%; and anti-GP2 IgA or IgG, 14.3%). For distinguishing CD from UC, the sensitivity, specificity, positive predictive value (PPV) and positive likelihood ratios (LR+) were 40%, 88.6%, 77.8%, and 3.51 for anti-GP2 IgG, 37.1%, 97.1%, 92.9%, and 13.0 for anti-GP2 IgA, and 54.3%, 85.3%, 79.2%, and 3.69 for anti-GP2 IgA or IgG. For CD diagnosis, the combination of anti-GP2 antibodies with ASCA IgA increased the sensitivity to 68.6% with moderate loss of specificity to 74.3%. Spearman's rank of order revealed a significantly positive correlation of anti-GP2 IgG with ileocolonic location of disease (L3) (P = 0.043) and a negative correlation of anti-GP2 IgA with biologic therapy (P = 0.012).Our findings suggest that anti-GP2 antibodies could serve as a biomarker for distinguishing patients with CD from patients with UC, and the combination of anti-GP2 antibodies with ASCA IgA may improve the predictive power.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease

Zhang¹,

Luo

et al. 2015

Medicine

View full text Add to dashboard Cite

show abstract

“…6,25 OmpC is an E. coli outer membrane protein that represents an immune response to the Enterobacteriaceae family. 32 In relation to increased risk of severe recurrence (≥ Rutgeerts i3), the total baseline quartile sum score (but not number of positive markers) was significantly greater in patients with, than patients without, severe recurrence at 18 months.…”

Section: Discussionmentioning

confidence: 88%

Serologic antibodies in relation to outcome in postoperative Crohn's disease

Hamilton

Kamm

Wright

et al. 2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Previous studies of serologic biomarkers have found associations with disease phenotype, disease progression and disease duration [4]. ASCA, anti-OmpC, anti-I2 and anti-CBir have been associated with complicated CD, progression of disease and need of surgery, whereas the presence of pANCA has been associated with an inflammatory behaviour and a less severe disease course [18][19][20][21][22][23][24][25]. Our findings of associations between CD-related surgery and positive ASCA IgA, positive ASCA IgG and negative pANCA are therefore in line with previous studies.…”

Section: Discussionmentioning

confidence: 99%

Serological antibodies and surgery in a population-based inception cohort of Crohn’s disease patients – the IBSEN study

Kristensen

Cvancarova

Høivik

et al. 2020

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

Introduction: Serological antibodies have been associated with complicated disease course in Crohn's disease (CD), including the need for surgery. Aim: The aim of this study was to investigate if a panel of relevant antibodies could predict surgery in a prospective population-based cohort of patients with CD. Methods: The population-based IBSEN cohort has been followed prospectively for 20 years. At the 10and 20-year follow-up, the following panel of serological antibodies was analysed: pANCA, ASCA IgA, ASCA IgG, anti-OmpC, anti-I2, and anti-CBir1. At the 20-year follow-up or until lost to follow-up, all CDrelated surgeries were registered. Results: Serum was available from 159 patients at 10-year follow-up and 135 patients at 20-year follow-up. In 113 patients, serum was available at both time points. No significant change of antibody status (positive vs. negative) was found from 10-year to 20-year follow-up. Negative pANCA, positive ASCA IgA and positive ASCA IgG at 10-year follow-up were all individually associated with increased risk for CD-related surgery. There was no association between anti-OmpC, anti-I2 or anti-CBir1 and CDrelated surgery. In a multiple regression model including disease location and behaviour, only stricturing or penetrating disease behaviour and negative pANCA remained significantly associated with higher odds for surgery. Conclusion: Positive ASCA IgA and IgG, and negative pANCA were associated with higher odds for CD-related surgery in univariate analysis. Since disease phenotype changes during the disease course, while serological antibodies are stable, our results support the use of pANCA, ASCA IgA and ASCA IgG as prognostic markers in CD.

show abstract

Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn’s disease

Cited by 14 publications

References 31 publications

Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease

Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease

Serologic antibodies in relation to outcome in postoperative Crohn's disease

Serological antibodies and surgery in a population-based inception cohort of Crohn’s disease patients – the IBSEN study

Contact Info

Product

Resources

About